DIRS.INFO The most relevant business & tech news

And I told her that many, many scientists work very, very hard," Kariko added. BioNTech said in June that about 1.5 billion people across the world had received its mRNA shot, co-developed with Pfizer (PFE.N). [1/11]Katalin Kariko and Drew Weissman win the 2023 Nobel Prize in Physiology or Medicine at the Karolinska Institute in Stockholm, Sweden October 2, 2023. The medicine prize kicks off this year's Nobel awards with the remaining five to be unveiled in coming days. The prizes, first handed out in 1901, were created by Swedish dynamite inventor and wealthy businessman Alfred Nobel.

Persons: Weissman, Katalin Kariko, Drew Weissman, Kariko, BioNTech, Rickard Sandberg, Susan Francia, immunologist, ”, Sir Andrew Pollard, Alfred Nobel, Swede Svante Paabo, Alexander Fleming, Karl Landsteiner, Niklas Pollard, Johan Ahlander, Ludwig Burger, Terje Solsvik, Andrew Cawthorne Organizations: Medicine, Nobel, Sweden's Karolinska Institute, University of Szeged, University of Pennsylvania, Pfizer, Karolinska Institute, TT News Agency, REUTERS Acquire, Boston University, Oxford University, AstraZeneca, Moderna, Thomson Locations: STOCKHOLM, COVID, Hungary, Pennsylvania, Szeged, U.S, Stockholm, Sweden, Frankfurt, Krisztina, Budapest, Oslo

☆ Explainer: What you need to know about RSV and the new vaccines
▼ + stars: | 2023-09-22 | by ( Michael Erman | ) www.reuters.com time to read: +4 min

That Pfizer (PFE.N) shot and one developed by GSK (GSK.L) in May became the first two RSV vaccines to win U.S. approval, for use in people aged 60 and over to prevent severe illness. Still, infants and older adults have a higher risk of developing severe RSV. RSV leads to 58,000 to 80,000 hospitalizations among children under age 5, and 60,000 to 160,000 hospitalizations among adults age 65 and older each year, according to the CDC. Early data suggests that the RSV shots are protective for at least two years, but it is not yet clear how often older adults will need to be revaccinated. Can I get the RSV shot alongside my COVID and flu shots?

Persons: Pfizer's, Synagis, it's, Jeffrey Duchin, you've, Michael Erman, Bhanvi, Caroline Humer, Bill Berkrot Organizations: . Centers for Disease Control, Prevention, Pfizer, GSK, CDC, FDA, Sanofi, AstraZeneca, Infectious Diseases Society of America, CVS, Humana, Thomson Locations: U.S, Aetna, New York, Bengaluru Edtiting

Sept 20 (Reuters) - AstraZeneca Pharmaceuticals LP (AZN.L) has been sued in the U.S. by a former senior director who claims the drugmaker refused to pay her nearly $130,000 in promised bonuses and stock options because she worked from home full-time. AstraZeneca, which is based in London and has U.S. headquarters in Delaware, did not immediately respond to a request for comment. The lawsuit claims AstraZeneca gave no prior notice that it would condition bonuses on whether employees reported to the office. Bodes accused AstraZeneca of breach of contract and failure to pay wages in violation of South Carolina law. She is seeking to recoup the money she claims she is owed along with other damages.

Persons: Elmarie Bodes, AstraZeneca, Bodes, Daniel Wiessner, Alexia Garamfalvi, Matthew Lewis Organizations: AstraZeneca Pharmaceuticals, AstraZeneca, Companies, South, Thomson Locations: U.S, South Carolina, London, Delaware, California, Albany , New York

☆ AstraZeneca succession sickness demands urgent fix
▼ + stars: | 2023-09-15 | by ( Aimee Donnellan | ) www.reuters.com time to read: +3 min

LONDON, Sept 15 (Reuters Breakingviews) - Can a CEO be worth $9 billion? That’s the question posed by the 4% fall in AstraZeneca’s (AZN.L) shares following an article stating boss Pascal Soriot may soon resign. The company has played down the report, and its stock has recovered, but the episode highlights its uncertain position were 64-year-old Soriot to leave. Without a clear succession plan, investors should prepare for further swings. Small wonder investors and analysts wonder whether AstraZeneca will be able to find a successor capable of replicating his success.

Persons: Pascal Soriot, AstraZeneca’s, Ivan Menezes, Debra Crew, Soriot, Susan Galbraith, David Fredrickson, Luke Miels, Soriot’s, Neil Unmack, Streisand Neto Organizations: Reuters, Pfizer, pharma, Novartis, Sanofi, GSK, AstraZeneca, Diageo, Thomson Locations: AstraZeneca’s, Swedish

☆ AstraZeneca seeks to calm CEO speculation after shares drop
▼ + stars: | 2023-09-11 | by ( Maggie Fick | ) www.reuters.com time to read: +2 min

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. The company initially declined to comment on the Mail on Sunday report, but later issued a statement saying: "We do not comment on market rumours. AstraZeneca shares closed down 3.2% after earlier touching their lowest since July 19. The Times' article focused on the retirement of Mene Pangalos, the long-time biopharmaceuticals head of research at AstraZeneca, which was announced in July. Reporting by Maggie Fick and Samuel Indyk; Editing by Tomasz Janowski and Mark PotterOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Pascal Soriot, Soriot, Mene Pangalos, Pangalos, Pascal, Maggie Fick, Samuel Indyk, Tomasz Janowski, Mark Potter Organizations: AstraZeneca, New York Stock Exchange, REUTERS, Reuters, Times, Thomson Locations: British

☆ AstraZeneca shares fall 3.6% to 7-1/2 week low
▼ + stars: | 2023-09-11 | by ( ) www.reuters.com time to read: 1 min

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsLONDON, Sept 11 (Reuters) - Shares in London-listed drugmaker AstraZeneca (AZN.L) declined as much as 3.6% on Monday, falling to their lowest since July 19. Reuters could not independently verify the information. AstraZeneca declined to comment on the report. Reporting by Samuel Indyk and Maggie Fick; Editing by Amanda CooperOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Pascal Soriot, Samuel Indyk, Maggie Fick, Amanda Cooper Organizations: AstraZeneca, New York Stock Exchange, REUTERS, Traders, Reuters, Thomson Locations: London

☆ AstraZeneca's Tagrisso-chemo combo results raise bar for J&J cancer drug-analysts
▼ + stars: | 2023-09-11 | by ( Maggie Fick | ) www.reuters.com time to read: +2 min

LONDON, Sept 11 (Reuters) - Data released on Monday by AstraZeneca (AZN.L) from a late-stage trial combining its blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer raises the bar for Johnson & Johnson's (JNJ.N) rival treatment, analysts said. A brief summary from the Phase 3 trial, called FLAURA2, was released in May, and the detailed data was presented on Monday in Singapore at the World Conference on Lung Cancer. The FLAURA2 trial showed that when adding chemotherapy to Tagrisso, the risk of disease progression or death is reduced by 38% when compared to Tagrisso alone. "With the strong FLAURA-2 data in hand and likely included in treatment guidelines soon, the hurdle is now pretty high in our view for MARIPOSA," the UBS note read. Barclays analysts said the FLAURA2 trial data presented on Monday included doctor and patient surveys that showed a strong preference for the convenience of a single therapy compared with combinations.

Persons: Johnson, Pascal Soriot, Michel Demare, Soriot, Maggie Fick, Emelia Sithole Organizations: AstraZeneca, Lung Cancer, Barclays, UBS, Reuters, Thomson Locations: Singapore, British, MARIPOSA

☆ AstraZeneca shares fall 4% to 7-1/2 week low
▼ + stars: | 2023-09-11 | by ( ) www.reuters.com time to read: +1 min

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsCompanies AstraZeneca PLC FollowLONDON, Sept 11 (Reuters) - Shares in London-listed drugmaker AstraZeneca (AZN.L) fell more than 4% on Monday, sliding to their lowest since July 19. An AstraZeneca spokesperson declined to comment on the report. Two of the analysts and the shareholder also mentioned that an article published on Monday in Britain's Times newspaper could have affected the shares, though it appeared to contradict the Mail on Sunday report. The Times' article focused on the retirement of Mene Pangalos, the long-time biopharmaceuticals head of research at AstraZeneca, which was announced in July.

Persons: Brendan McDermid, Pascal Soriot, Mene Pangalos, Pangalos, Pascal, Maggie Fick, Samuel Indyk, Amanda Cooper, Tomasz Janowski Organizations: AstraZeneca, New York Stock Exchange, REUTERS, drugmaker's, Reuters, Britain's Times, Times, Thomson Locations: London

☆ Miners boost FTSE 100 on China optimism; Vistry jumps
▼ + stars: | 2023-09-11 | by ( ) www.reuters.com time to read: +1 min

Signage for the London Stock Exchange Group is seen outside of offices in Canary Wharf in London, Britain, August 3, 2023. REUTERS/Toby Melville/File Photo Acquire Licensing RightsSummaryCompanies FTSE 100 up 0.6%, FTSE 250 adds 0.4%Sept 11 (Reuters) - The UK's exporter-heavy FTSE 100 index opened higher on Monday boosted by miners after positive China data signalled stability in the world's second-largest economy, while Vistry shares jumped after the homebuilder kept its annual profit outlook. The blue-chip FTSE 100 index (.FTSE) rose 0.6% in early trade, while the mid-cap FTSE 250 index (.FTMC) was up 0.4%. Vistry Group (VTYV.L) jumped 14.4% after the British homebuilder said it would merge its affordable-housing business 'Partnerships' with its Housebuilding operations, while maintaining its annual profit forecast. Reporting by Siddarth S in Bengaluru; Editing by Rashmi AichOur Standards: The Thomson Reuters Trust Principles.

Persons: Toby Melville, British homebuilder, Pascal Soriot, Siddarth, Rashmi Organizations: London Stock Exchange, REUTERS, Vistry, AstraZeneca, The Mail, Barclays, Reuters, Thomson Locations: Canary Wharf, London, Britain, China, British, Bengaluru

He said that once implemented, the prices on negotiated drugs will decrease for up to 9 million seniors who currently pay as much as $6,497 in out-of-pocket costs per year for these prescriptions. This kicks off the negotiation process for the 10 drugs whose new prices will go into effect in 2026. U.S. laws had prohibited Medicare from negotiating pharmaceutical prices as part of its prescription drug program that began about 20 years ago. CMS Director Dr. Meena Seshamani said Medicare plans to use a review process to make sure insurance companies keep clinically appropriate access to negotiated drugs. Two analysts said they expect the negotiated prices to move beyond Medicare and affect commercial markets for these drugs by 2026, when they come into effect.

Persons: Joe Biden, Jonathan Ernst, Biden, Joe Biden’s, Januvia, Xarelto, Johnson, Boehringer Ingelheim, Eli Lilly's, Jardiance, Mohit Bansal, Entresto, Eli Lilly, Merck, Bristol Myers, Giovanni Caforio, Caforio, enrollees, Meena Seshamani, Stelara, Amgen, Evan Seigerman, Patrick Wingrove, Mike Erman, Manas Mishra, Nandita Bose, Caroline Humer, Bill Berkrot Organizations: Social Security, University of Tampa, REUTERS, U.S, Bristol Myers Squibb, Pfizer, Merck, Co's, Johnson, Novo Nordisk, NYSE Arca Pharmaceutical, U.S . Centers, Medicare, Medicaid Services, Reuters Graphics Wells, Novartis, AstraZeneca, Bristol, J, U.S . Department of Health, Human Services, BMO Capital, Thomson Locations: Tampa , Florida, U.S, Amgen's, Jardiance, Germany, Bengaluru, Washington

REUTERS/Brendan McDermid/File Photo/File Photo Acquire Licensing RightsAug 25 (Reuters) - AstraZeneca (AZN.L) said on Friday it has sued the U.S. government to block parts of a program that gives the Medicare health insurance plan the power to negotiate lower drug prices. The program faces at least seven other court challenges, including from leading industry group PhRMA and drugmakers Johnson & Johnson (JNJ.N), Merck & Co (MRK.N), Bristol Myers Squibb (BMY.N) and privately-held Boehringer Ingelheim. The drug price negotiation program is part of President Joe Biden's signature Inflation Reduction Act (IRA). ‍AstraZeneca said the program would deter continued development of treatments such as its cancer drug Lynparza and rare blood disorder drug Soliris, which carry orphan drug status for multiple conditions. An HHS spokesperson said in a statement that the agency "will vigorously defend the President's drug price negotiation law, which is already helping to lower healthcare costs for seniors and people with disabilities."

Persons: Brendan McDermid, drugmakers Johnson, Johnson, Joe Biden's, AstraZeneca, Bhanvi, Dhanya Ann Thoppil, Shilpi Majumdar Organizations: AstraZeneca, New York Stock Exchange, REUTERS, U.S, Merck & Co, Bristol Myers Squibb, U.S . Department of Health, Human Services, Thomson Locations: British, Delaware, United States, U.S, Bengaluru

FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. The drug price negotiation program is part of President Joe Biden's signature Inflation Reduction Act (IRA). The program faces several other court challenges, including from leading industry groups and other drug companies. ‍AstraZeneca said it was filing a legal challenge in a bid to "protect timely access to medicines for orphan indications" in the United States. Reporting by Bhanvi Satija in Bengaluru; Editing by Dhanya Ann Thoppil and Shilpi MajumdarOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Joe Biden's, AstraZeneca, Bhanvi, Dhanya Ann Thoppil, Shilpi Majumdar Organizations: AstraZeneca, New York Stock Exchange, REUTERS, drugmaker AstraZeneca, Thomson Locations: United States, Bengaluru

☆ Novo says Wegovy drug helps obese people with heart failure in trial
▼ + stars: | 2023-08-25 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

FILE PHOTO: A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. The trial with 529 volunteers focused on a heart condition known as preserved ejection fraction, or HFpEF, where heart muscles stiffen and draw in less blood, mainly affecting overweight people. HFpEF accounts for about half of heart failure cases, with symptoms including shortness of breath and swelling of extremities. Showing specific medical benefits is crucial for Novo's push to move Wegovy beyond its image as a lifestyle drug. It is unclear, though, what conclusions regulators and physicians will draw from the STEP HFpEF results because other heart failure treatments are emerging.

Persons: Jim Vondruska, Wegovy, ”, Martin Lange, Danish drugmaker, Farxiga, Lars Fruergaard Jorgensen, Ludwig Burger, Jason Neely, Mark Potter Organizations: REUTERS, Novo Nordisk, Novartis, Reuters, Thomson Locations: Chicago , Illinois, U.S, Danish, Novo, United States, Europe, Germany

☆ How soaring demand for Ozempic and Wegovy is altering Denmark’s economy
▼ + stars: | 2023-08-21 | by ( Anna Cooban | ) edition.cnn.com time to read: +3 min

Its maker, Novo Nordisk (NONOF), has raked in almost 49 billion Danish krone in profit ($7 billion) over the first six months of this year, up 32% from the same period in 2022. Novo Nordisk also produces Ozempic, a drug developed to treat type 2 diabetes but which contains the same active ingredient as Wegovy. Surging demandShares in Novo Nordisk have soared 34% since the start of 2023 to give the company a market capitalization of 2.2 trillion Danish krone ($322 billion). The stock shot up earlier this month after Novo Nordisk published the results of a five-year trial on the impact of Wegovy on cardiovascular disease. Novo Nordisk now expects its profits to grow by up to 37% this year, much higher growth than the maximum 19% rise it forecast in February.

Persons: Jens Naervig Pedersen, Pedersen, Jaap Arriens, ” Pedersen, “ We’ve, Andrew Kenningham, “, juggernauts Roche Organizations: London CNN, Nordic, Novo Nordisk, Danish, Danske Bank, European Central Bank, CNN, Capital Economics, AstraZeneca, Kaiser Family Foundation Locations: United States, Denmark, Danish, Europe

Aug 21 (Reuters) - The U.S. Food and Drug Administration on Monday approved Pfizer's (PFE.N) respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their babies. An FDA panel of outside experts backed the safety and effectiveness of Pfizer's RSV vaccine for women in their second and third trimesters earlier in May. RSV is a common respiratory virus that usually causes mild, cold-like symptoms but can also lead to serious illness and hospitalization. Infants are at greatest risk for severe illness from RSV. An estimated 58,000 to 80,000 children below the age of five years are hospitalized every year due to RSV infection in the U.S., according to government data.

Persons: Pfizer, Mariam Sunny, Bhanvi, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: U.S . Food, Drug Administration, FDA, Pfizer, U.S . Centers for Disease Control, Sanofi, AstraZeneca, GSK, Thomson Locations: U.S, United States, Bengaluru, New York

☆ These 10 medications are likely targets for Medicare price negotiations this fall
▼ + stars: | 2023-08-10 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

Though it is still unclear which 10 drugs Medicare will select, several pharmaceutical companies have already revealed in court filings that they expect four of their blockbuster medications to be targeted. Bristol-Myers Squibb and Johnson & Johnson , in separate filings, said their blood thinners Eliquis and Xarelto will be subject to the negotiations this year. The list price of Januvia has surged 275% since 2006, according to the AARP. Johnson & Johnson reported $2.47 billion in revenue from Xarelto. "More and more people face cost-sharing that is directly affected by drug price increases," Leigh Purvis, who analyzes health-care costs for AARP, told reporters on a call Thursday.

Persons: Daniel Acker, Merck, Johnson, Abbvie, Imbruvica, Jardiance, Boehringer Ingelheim, Amgen Symbicort, Pfizer Xtandi, Breo, Biden, Januvia, Eliquis, Xarelto, Leigh Purvis Organizations: Merck, Co, Inc, Bloomberg, Getty, Medicare, Services, Myers Squibb, Johnson, Pharmacy, AstraZeneca Ibrance, Pfizer, Astellas Pharma, GSK, AARP, Bristol Myers Squibb, Jama Network, Industry Locations: Bristol, U.S, Januvia, Xarelto

In a filing to Shanghai's stock exchange, CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca. AstraZeneca said the deal would support investigational mRNA vaccines in its early pipeline. The country approved in March its first homegrown mRNA vaccine against COVID, developed by CSPC Pharmaceutical Group (1093.HK). CanSino has been working on its own mRNA COVID vaccine, and said in February it was in discussion with Chinese regulators around the protocol for a late-stage study for its COVID mRNA booster vaccine, CS-2034. It also comes after vaccine maker Moderna (MRNA.O), which has said that it was keen to sell its mRNA vaccine to China, announced a deal last month to develop and manufacture mRNA medicines in the country.

Persons: Dado Ruvic, Biologics, CanSino, Wang Wentao, Casey Hall, Ludwig Burger, Miyoung Kim, Mark Potter, Himani Organizations: AstraZeneca, REUTERS, HK, CSPC Pharmaceutical, CS, Communist Party, China's Commerce, Moderna, Thomson Locations: Swedish, China, Frankfurt

☆ US CDC panel recommends Sanofi-AstraZeneca's preventive RSV therapy for babies
▼ + stars: | 2023-08-03 | by ( ) www.reuters.com time to read: +1 min

[1/2] Sanofi logo at the company's headquarters during the annual results news conference in Paris, France, February 4, 2022. REUTERS/Benoit Tessier/File PhotoCompanies AstraZeneca PLC FollowSanofi SA FollowAug 3 (Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) said its advisory panel on Thursday recommended use of Sanofi (SASY.PA) and partner AstraZeneca's (AZN.L) antibody therapy to prevent respiratory syncytial virus (RSV) in infants and toddlers. The Advisory Committee on Immunization Practices unanimously recommended nirsevimab for preventing lower respiratory tract disease in newborns and infants below eight months of age born during or entering their first RSV season. It also recommended its use in children aged 8-19 months who remain vulnerable to severe RSV disease through their second such season. The therapy, branded as Beyfortus, will be available in the U.S. ahead of the upcoming 2023-24 RSV season, Sanofi said.

Persons: Benoit Tessier, AstraZeneca's, Sanofi, Mrinmay Dey, Mariam Sunny Organizations: Sanofi, REUTERS, Companies AstraZeneca, U.S . Centers for Disease Control, Prevention, U.S . Food, Drug Administration, Thomson Locations: Paris, France, U.S, Bengaluru

SummaryCompanies Q2 sales and earnings beat estimatesReiterates full-year guidanceNo revenue from COVID vaccine in Q2Shares up 3.1% in early tradeCompany is largest drugmaker in ChinaLONDON, July 28 (Reuters) - AstraZeneca (AZN.L) on Friday delivered better-than-expected profits and sales in the second quarter as a strong performance of its blockbuster cancer drugs helped offset the loss of COVID-19 vaccine sales. The Anglo-Swedish drugmaker posted an adjusted profit of $2.15 per share, up 25% and exceeding the $1.98 per share expected in company-compiled consensus estimates. Total revenue in the quarter was $11.4 billion, up 6% and beating company-compiled analyst estimates of $10.97 billion. Excluding COVID medicines, sales in China grew by 7% at constant exchange rates in the quarter, the fourth consecutive quarter of growth on that basis. AstraZeneca is the largest drugmaker in China, which accounted for 13% of last year's revenue.

Persons: Swedish drugmaker, Pascal Soriot, Markus Manns, Alexion, drugmaker, Maggie Fick, Radhika Anilkumar, Nivedita Bhattacharjee, Josephine Mason Organizations: AstraZeneca, UK's, Pfizer, Moderna, U.S, Union Investment, Thomson Locations: China LONDON, Swedish, China, London, Bengaluru

☆ AstraZeneca to buy Pfizer's rare disease gene therapy portfolio for up to $1 bln
▼ + stars: | 2023-07-28 | by ( ) www.reuters.com time to read: +1 min

[1/2] FILE PHOTO-Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File PhotoJuly 28 (Reuters) - AstraZeneca (AZN.L) said on Friday its unit Alexion has agreed to buy U.S. drugmaker Pfizer's <PFE.N> early-stage rare disease gene therapy portfolio for up to $1 billion, plus royalties on sales. AstraZeneca bought Alexion in 2021. It focuses on rare diseases and plans to close the deal in the third quarter, the British drugmaker said. AAV capsids have been shown to be an effective mechanism for delivering therapeutic gene cargos for gene therapy and gene editing, the company said.

Persons: Dado Ruvic, Alexion, drugmaker, AAV, Yadarisa, Nivedita Organizations: AstraZeneca, REUTERS, Thomson Locations: Bengaluru

SummaryCompanies Plans to file trial data with FDAComments sooth some investor concernsAbsence of "clinically meaningful" in interim trial data worried investorsLONDON, July 28 (Reuters) - AstraZeneca Chief Executive Pascal Soriot said on Friday the company is "very encouraged" by interim data from a key lung cancer drug trial, but he did not explain why the company had not declared results as "clinically meaningful". The drugmaker's (AZN.L) shares fell by as much as 8% earlier this month after the company released interim data from the late-stage clinical trial called TROPION-Lung01 testing an experimental precision drug called datopotamab deruxtecan. Speaking to media on Friday after the company released better-than-expected quarterly results, Soriot said people would understand when full results are released why the company did not use that description, but he did not comment further. The company said on Friday it will continue with its plan to file data from the trial with the U.S. Food and Drug Administration (FDA), soothing some investor concerns. In a briefing with analysts, Susan Galbraith, executive vice president of oncology R&D, said the FDA response to the data so far had been "encouraging".

Persons: Pascal Soriot, Soriot, Susan Galbraith, Maggie Fick, Josephine Mason, David Evans, Susan Fenton Organizations: LONDON, AstraZeneca, U.S . Food, Drug Administration, FDA, U.S, Thomson

☆ What we hope to see from 9 Club stocks out with earnings in the week ahead
▼ + stars: | 2023-07-22 | by ( Zev Fima | ) www.cnbc.com time to read: +14 min

Looking to next week, earnings season will ramp up — and though we'll get some important economic data, expect the corporate releases and management commentary on the post-game calls to be firmly in the driver's seat. Here are two important things to know for the week ahead. Quarterly earnings : As important as economic releases are, it's earnings that will garner the bulk of investors' attention. For those looking to review first-quarter performance ahead of these releases, keep our first-quarter earnings report card handy. Here's the full rundown of all the important domestic data in the week ahead.

Persons: Dow, we'll, we've, Lawrence Yun, Jerome Powell's, Sartorius, Sartorius preannounced, It's, management's, We'll, Tesla, Ford's, Sherwin, Williams, Archer, Clark, Lam, Edwards Lifesciences, Hewlett, Northrop, Dr Pepper, Davidson, Jim Cramer's, Jim Cramer, Jim, Spencer Platt Organizations: Nasdaq, Economic, National Association of Realtors, Nine, GE Healthcare, Microsoft, YouTube, Linde, LIN, Honeywell, Aerospace, Technologies, Ford, Procter & Gamble, Dynex, HBT, Hope Bancorp, NXP Semiconductors, Cadence Design Systems, Whirlpool, Logitech International, Liberty Global, Verizon Communications, General Motors, General Electric, GE, Spotify, Raytheon Technologies, Daniels, Midland, Albertsons Companies, ACI, Polaris Industries, Inc, Dow Chemical, DOW, Xerox, Texas Instruments, WM, Canadian National Railway Company, Chubb Corporation, Universal Health Services, Powell, Boeing, Hilton, Union Pacific, General Dynamics, Quest Diagnostics, Otis Worldwide, Grill, Lam Research, eBay, EBAY, Mattel, Hewlett Packard, L3Harris Technologies, Gross, Royal Caribbean Cruises, Southwest Airlines, Mastercard, Myers Squibb, Northrop Grumman, Hertz, Tractor Supply Company, HCA Healthcare, Boston, Hershey, Comcast, Harley, Norfolk Southern, Intel, Mobile, United States Steel Corp, KLA Corporation, Boston Beer Company, Nation Entertainment, Texas, Procter, Gamble, Exxon Mobil, Chevron, Charter Communications, AstraZeneca, Colgate, Palmolive, Newell Brands, Sanofi, Dwight, Jim Cramer's Charitable, CNBC, New York Stock Exchange, Getty Locations: U.S, Hollywood, Cleveland, Corning, Kimberly, Bristol, Norfolk

☆ US FDA approves Sanofi-AstraZeneca's preventive RSV therapy for babies
▼ + stars: | 2023-07-17 | by ( ) www.reuters.com time to read: +2 min

July 17 (Reuters) - The U.S. Food and Drug Administration (FDA) said on Monday it had approved Sanofi (SASY.PA) and partner AstraZeneca's (AZN.L) antibody therapy to prevent respiratory syncytial virus (RSV) in infants and toddlers. The therapy, branded Beyfortus, was approved for preventing lower respiratory tract disease in infants born during or entering their first RSV season, and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second such season. The companies plan to make Beyfortus available in the United States ahead of the upcoming RSV season, Sanofi said, adding that it plans to share more information about the therapy's price closer to the season. RSV is a leading cause of hospitalizations in infants and so far Swedish Orphan Biovitrum's (SOBIV.ST) treatment, Synagis, was the only approved preventive therapy in the United States for high-risk infants. The therapy comes with warnings and precautions about serious hypersensitivity reactions, and should be given with caution to infants and children with clinically significant bleeding disorders, the FDA said.

Persons: AstraZeneca's, Sanofi, Beyfortus, Bhanvi Satija, Shinjini Ganguli, Maju Samuel Organizations: U.S . Food, Drug Administration, Sanofi, American Academy of Pediatrics, FDA, Thomson Locations: U.S, United States, Bengaluru

☆ UBS upgrades Big Pharma stock after shares drop on poor drug results
▼ + stars: | 2023-07-13 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

UBS upgraded AstraZeneca 's stock to a "buy" rating despite the drugmaker's trial of a lung cancer medication recently delivering poor results. The investment bank said the subsequent drop in the pharma giant's stock price now meant that "investors can come back to the stock for the performance of in-market products." London-listed shares of AstraZeneca dropped by 8% in a single day, the most in years, after releasing the results of the "TropionLung01" trial for drug candidate "Dato-DXd." UBS expects shares of AstraZeneca to rise by 27% to £13 ($16.8) a share over the next 12 months. These include Imfinzi, a drug for bile duct or gallbladder cancer, and Tagrisso, a treatment for non-small cell lung cancer in adults.

Persons: Michael Leuchten, UBS Michael Leuchten AZN Organizations: UBS, AstraZeneca, pharma, DXd, FDA, Johnson Locations: London, Swiss, Tagrisso

BEIJING, July 5 (Reuters) - China's Commerce Minister told foreign pharmaceuticals firms they can expect "more development opportunities" during a roundtable on Wednesday, his ministry said, as drugmakers bemoan government procurement policies pricing them out of the market. Foreign pharmaceuticals firms have struggled to cement any inroads they have made into the world's second-largest economy, with the government maintaining a drug procurement programme that forces them to slash their prices and refusing to approve the use of any foreign COVID-19 vaccines during the pandemic. But as China pursues home-grown modernisation it will also open up "more development opportunities for foreign-funded enterprises, including the pharmaceutical industry," Wang told the meeting. Wang told the meeting on Wednesday that his ministry will expand the channels of communication for responding to and solving concerns, with the meeting resulting in 25 specific suggestions to be taken forward. Reporting by Joe Cash; Additional reporting by Kevin Yao;Editing by Elaine HardcastleOur Standards: The Thomson Reuters Trust Principles.

Persons: Roche, Takeda, Wang Wentao, Wang, Li Qiang, Li, drugmakers, Joe Cash, Kevin Yao, Elaine Hardcastle Organizations: China's Commerce, AstraZeneca, Bayer, Merck, Novo Nordisk, Pfizer, Sanofi, Moderna, Wednesday, Economic, Thomson Locations: BEIJING, China, Tianjin

Search resuls for: "AZN"

25 mentions found